Endothelial-Derived Hyperpolarizing Factor (EDHF)

Is there more than one?

Christopher Triggle, H. D. Dong, Hong Ding, G. J. Waldron, W. C. Cole

Research output: Contribution to journalArticle

Abstract

It is now well established that the pharmacological properties of EDRF reflect those of nitric oxide (NO). Furthermore, in some blood vessels, prostacyclin (PGI2) also contributes to endothelium-dependent vasorelaxation. However, there is now increasing evidence, particularly from resistance vessels, that a factor(s), other than NO or PGI2, may play an important role in mediating endothelium-dependent hyperpolarization of vascular smooth muscle (Mombouli & Vanhoutte, 1997; Waldron et al. 1996). Recent studies from our laboratory indicate that in a large conduit vessel, the rabbit carotid artery, EDHF possesses the properties of a cytochrome P450 arachidonic acid product (Dong et al. 1997), whereas in mesenteric vessels from both the guinea pig and the rat, cytochrome P450 inhibitors have minimal effects on non-NO/PGI2 endothelium-dependent vasorelaxation. These data strongly suggest that EDHF is not a single entity and that tissue and species differences may exist.

Original languageEnglish
Pages (from-to)286-287
Number of pages2
JournalProceedings of the Western Pharmacology Society
Volume41
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Epoprostenol
Endothelium
Vasodilation
Cytochrome P-450 Enzyme System
Nitric Oxide
Vascular Smooth Muscle
Carotid Arteries
Arachidonic Acid
Oxides
Blood Vessels
Guinea Pigs
Pharmacology
Rabbits

ASJC Scopus subject areas

  • Pharmacology

Cite this

Endothelial-Derived Hyperpolarizing Factor (EDHF) : Is there more than one? / Triggle, Christopher; Dong, H. D.; Ding, Hong; Waldron, G. J.; Cole, W. C.

In: Proceedings of the Western Pharmacology Society, Vol. 41, 1998, p. 286-287.

Research output: Contribution to journalArticle

@article{74ec9eb123b9469c88881622026e226c,
title = "Endothelial-Derived Hyperpolarizing Factor (EDHF): Is there more than one?",
abstract = "It is now well established that the pharmacological properties of EDRF reflect those of nitric oxide (NO). Furthermore, in some blood vessels, prostacyclin (PGI2) also contributes to endothelium-dependent vasorelaxation. However, there is now increasing evidence, particularly from resistance vessels, that a factor(s), other than NO or PGI2, may play an important role in mediating endothelium-dependent hyperpolarization of vascular smooth muscle (Mombouli & Vanhoutte, 1997; Waldron et al. 1996). Recent studies from our laboratory indicate that in a large conduit vessel, the rabbit carotid artery, EDHF possesses the properties of a cytochrome P450 arachidonic acid product (Dong et al. 1997), whereas in mesenteric vessels from both the guinea pig and the rat, cytochrome P450 inhibitors have minimal effects on non-NO/PGI2 endothelium-dependent vasorelaxation. These data strongly suggest that EDHF is not a single entity and that tissue and species differences may exist.",
author = "Christopher Triggle and Dong, {H. D.} and Hong Ding and Waldron, {G. J.} and Cole, {W. C.}",
year = "1998",
language = "English",
volume = "41",
pages = "286--287",
journal = "Proceedings of the Western Pharmacology Society",
issn = "0083-8969",
publisher = "Western Pharmacology Society",

}

TY - JOUR

T1 - Endothelial-Derived Hyperpolarizing Factor (EDHF)

T2 - Is there more than one?

AU - Triggle, Christopher

AU - Dong, H. D.

AU - Ding, Hong

AU - Waldron, G. J.

AU - Cole, W. C.

PY - 1998

Y1 - 1998

N2 - It is now well established that the pharmacological properties of EDRF reflect those of nitric oxide (NO). Furthermore, in some blood vessels, prostacyclin (PGI2) also contributes to endothelium-dependent vasorelaxation. However, there is now increasing evidence, particularly from resistance vessels, that a factor(s), other than NO or PGI2, may play an important role in mediating endothelium-dependent hyperpolarization of vascular smooth muscle (Mombouli & Vanhoutte, 1997; Waldron et al. 1996). Recent studies from our laboratory indicate that in a large conduit vessel, the rabbit carotid artery, EDHF possesses the properties of a cytochrome P450 arachidonic acid product (Dong et al. 1997), whereas in mesenteric vessels from both the guinea pig and the rat, cytochrome P450 inhibitors have minimal effects on non-NO/PGI2 endothelium-dependent vasorelaxation. These data strongly suggest that EDHF is not a single entity and that tissue and species differences may exist.

AB - It is now well established that the pharmacological properties of EDRF reflect those of nitric oxide (NO). Furthermore, in some blood vessels, prostacyclin (PGI2) also contributes to endothelium-dependent vasorelaxation. However, there is now increasing evidence, particularly from resistance vessels, that a factor(s), other than NO or PGI2, may play an important role in mediating endothelium-dependent hyperpolarization of vascular smooth muscle (Mombouli & Vanhoutte, 1997; Waldron et al. 1996). Recent studies from our laboratory indicate that in a large conduit vessel, the rabbit carotid artery, EDHF possesses the properties of a cytochrome P450 arachidonic acid product (Dong et al. 1997), whereas in mesenteric vessels from both the guinea pig and the rat, cytochrome P450 inhibitors have minimal effects on non-NO/PGI2 endothelium-dependent vasorelaxation. These data strongly suggest that EDHF is not a single entity and that tissue and species differences may exist.

UR - http://www.scopus.com/inward/record.url?scp=33748165629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748165629&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 286

EP - 287

JO - Proceedings of the Western Pharmacology Society

JF - Proceedings of the Western Pharmacology Society

SN - 0083-8969

ER -